|
|
||||
|
Published by : PROFESSIONAL MEDICAL PUBLICATIONS |
||||
|
ISSN 1681-715X |
||||
|
||||
|
- |
||||
|
ORIGINAL ARTICLE |
||||
|
- |
||||
|
Volume 25 |
January - March 2009 |
Number 1 |
||
|
|
||||
|
|
||||
|
|
||||
|
Published by : PROFESSIONAL MEDICAL PUBLICATIONS |
||||
|
ISSN 1681-715X |
||||
|
||||
|
- |
||||
|
ORIGINAL ARTICLE |
||||
|
- |
||||
|
Volume 25 |
January - March 2009 |
Number 1 |
||
|
|
||||
|
|
||||
Effect of Hydroxyurea on Thalassemia Major and
Thalassemia Intermedia in Iranian PatientsMehrnoosh Kosaryan1, Koorosh Vahidshahi2, Hosein Karami3, Sara Ehteshami4
ABSTRACT
Background: Hydroxyurea has been used in thalassemia major (T.M.) and thalassemia intermedia patients since 1994 with some success in different centers. The objective was to evaluate the effect and possible side effects of hydroxyurea in these patients.
Methodology: This was a descriptive study done in 2007 after nine years of initiation of Hydroxyurea. Medical records of 1050 patients were reviewed. Patients who had received hydroxyurea for at least three continuous months were enrolled into the study. Clinical and laboratory data during six months before and six month after starting hydroxyurea were compared.
Results: Two hundred ninety seven patients were enrolled of these two hundred forty eight (83.8%) were thalassemia major and forty eight (16.2%) were thalassemia intermedia. Dose of hydroxyurea was 15.5±6.4mg/kg /day and duration was 5.2±2 years (ranging 0.5-9 years). Transfusions were completely stopped in one hundred eleven (44.7%) of thalassemia major patients with a mean Hb of 10g/dl. After 22.5±18 months, using Desferal was stopped in sixty six (26.6%) patients. The reasons for stopping hydroxiurea were "ineffectiveness" in 20%, "poor compliance" in 12.4% and side effects in 13.4% of patients. The side effects were nausea, palpitation, transient leucopenia and transient raising of creatinin.
Conclusion: Hydroxyurea is effective and safe in thalassemia major and thalassemia intermedia patients and saves them from side effects of blood transfusions.
KEY WORDS: Thalassemia major, Thalassemia intermedia, Hydroxyurea, Iran.
Pak J Med Sci January - March 2009 Vol. 25 No. 1 74-78
How to cite this article:
Kosaryan M, Vahidshahi K, Karami H, Ehteshami S. Effect of Hydroxyurea on Thalassemia Major and Thalassemia Intermedia in Iranian Patients. Pak J Med Sci 2009;25(1):74-78.
1. Mehrnoosh Kosaryan,
Professor, Dept. of Pediatrics,
2. Koorosh Vahidshahi,
Assistant Professor, Dept. of Pediatrics,
3. Hosein Karami,
Assistant Professor, Dept. of Pediatrics,
4. Sara Ehteshami,
General Practitioner,
Mazandaran University of Medical Science and
Health Services, Iran.Correspondence
Mehrnoosh Kosaryan,
Thalassemia Research Center, Boo Ali Sina Hospital,
Mazandaran, Sari, Iran.
E-mail: mekowsarian@gmail.com
* Received for Publication: August 23, 2007
* Revision Received: July 24, 2008
* Revision Accepted: September 23, 2008
HOME | SEARCH | CURRENT ISSUE | PAST ISSUES
Professional
Medical Publications
Room No. 522, 5th Floor, Panorama Centre
Building No. 2, P.O. Box 8766, Saddar, Karachi - Pakistan.
Phones : 5688791, 5689285 Fax : 5689860
pjms@pjms.com.pk
